Diagnosing Resistance to a Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitor
The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
Letters6 March 2018Diagnosing Resistance to a Proprotein Convertase Subtilisin/Kexin Type 9 InhibitorMichael D. Shapiro, DO, Joshua Miles, BS, Hagai Tavori, PhD, and Sergio Fazio, MD, PhDMichael D. Shapiro, DOOregon Health & Science University, Portland, Oregon (M.D.S., J.M., H.T., S.F.)Search for more papers by this author, Joshua Miles, BSOregon Health & Science University, Portland, Oregon (M.D.S., J.M., H.T., S.F.)Search for more papers by this author, Hagai Tavori, PhDOregon Health & Science University, Portland, Oregon (M.D.S., J.M., H.T., S.F.)Search for more papers by this author, and Sergio Fazio, MD, PhDOregon Health & Science University, Portland, Oregon (M.D.S., J.M., H.T., S.F.)Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/M17-2485 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail Background: The discovery of proprotein convertase subtilisin/kexin type 9 (PCSK9) revolutionized the understanding of lipoprotein metabolism (1). Rapid translation of genetic insights led to the development of a new class of therapeutic agents that antagonize plasma PCSK9 and cause remarkable reductions (between 45% and 75%) in low-density lipoprotein (LDL) cholesterol levels. A large randomized controlled trial recently showed that adding a PCSK9 inhibitor in patients with established vascular disease who were already treated with optimized statin therapy caused statistically significant reductions in rates of myocardial infarction and stroke (2). Most patients receiving a PCSK9 inhibitor respond with marked reductions in ...References1. Abifadel M, Varret M, Rabès JP, Allard D, Ouguerram K, Devillers M, et al. Mutations in PCSK9 cause autosomal dominant hypercholesterolemia. Nat Genet. 2003;34:154-6. [PMID: 12730697] CrossrefMedlineGoogle Scholar2. Sabatine MS, Giugliano RP, Keech AC, Honarpour N, Wiviott SD, Murphy SA, et al; FOURIER Steering Committee and Investigators. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med. 2017;376:1713-22. [PMID: 28304224] doi:10.1056/NEJMoa1615664 CrossrefMedlineGoogle Scholar3. Raal FJ, Giugliano RP, Sabatine MS, Koren MJ, Langslet G, Bays H, et al. Reduction in lipoprotein(a) with PCSK9 monoclonal antibody evolocumab (AMG 145): a pooled analysis of more than 1,300 patients in 4 phase II trials. J Am Coll Cardiol. 2014;63:1278-88. [PMID: 24509273] doi:10.1016/j.jacc.2014.01.006 CrossrefMedlineGoogle Scholar4. Tavori H, Fan D, Blakemore JL, Yancey PG, Ding L, Linton MF, et al. Serum proprotein convertase subtilisin/kexin type 9 and cell surface low-density lipoprotein receptor: evidence for a reciprocal regulation. Circulation. 2013;127:2403-13. [PMID: 23690465] doi:10.1161/CIRCULATIONAHA.113.001592 CrossrefMedlineGoogle Scholar Author, Article, and Disclosure InformationAffiliations: Oregon Health & Science University, Portland, Oregon (M.D.S., J.M., H.T., S.F.)Acknowledgment: The authors thank Paul Ziajka, MD, for contributing plasma samples for 1 of the participants.Grant Support: Partially supported by National Institutes of Health (National Heart, Lung, and Blood Institute) R01 grant HL-132985 (Dr. Fazio).Disclosures: Disclosures can be viewed at www.acponline.org/authors/icmje/ConflictOfInterestForms.do?msNum=M17-2485.Reproducible Research Statement:Study protocol and statistical code: Not available. Data set: Available from Dr. Shapiro (e-mail, [email protected]edu).This article was published at Annals.org on 28 November 2017. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited byGenetics, Safety, Cost-Effectiveness, and Accessibility of Injectable Lipid-Lowering Agents: A Narrative ReviewMechanisms of unusual response to lipid-lowering therapy: PCSK9 inhibitionRecent Update on the Development of PCSK9 Inhibitors for Hypercholesterolemia TreatmentPCSK9 Inhibitor Wars: How Does Inclisiran Fit in with Current Monoclonal Antibody Inhibitor Therapy? Considerations for Patient SelectionPCSK9 Monoclonal Antibodies: New Developments and Their Relevance in a Nucleic Acid–Based Therapy EraPharmacological rationale for the very early treatment of acute coronary syndrome with monoclonal antibodies anti-PCSK9Inhibitory Antibodies against PCSK9 Reduce Surface CD36 and Mitigate Diet-Induced Renal LipotoxicityThe promising novel therapies for familial hypercholesterolemiaThe Emerging Roles of Intracellular PCSK9 and Their Implications in Endoplasmic Reticulum Stress and Metabolic DiseasesThe Effect of Proprotein Convertase Subtilisin Kexin Type 9 Inhibitors on Circulating Endothelial Progenitor Cells in Patients with Cardiovascular DiseasePCSK9 inhibitors revisited: Effectiveness and safety of PCSK9 inhibitors in a real-life Spanish cohortInclisiran: a small interfering RNA strategy targeting PCSK9 to treat hypercholesterolemiaHepatic Sensing Loop Regulates PCSK9 Secretion in Resp
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease
Sabatine, M. S., Giugliano, R. P., Keech, A. C., Honarpour, N., Wiviott, S. D., Murphy, S. A., Kuder, J. F., Wang, H., Liu, T., Wasserman, S. M., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1615664 · Cited by 6,138
Mutations in PCSK9 cause autosomal dominant hypercholesterolemia
Abifadel, M., Varret, M., Rabès, J.-P., Allard, D., Ouguerram, K., Devillers, M., Cruaud, C., Benjannet, S., Wickham, L., Erlich, D., et al. (2003) · Nature Genetics · doi:10.1038/ng1161 · Cited by 2,985
Cited by
PCSK9: From Basic Science Discoveries to Clinical Trials
Shapiro, M. D., Tavori, H., & Fazio, S. (2018) · Circulation Research · doi:10.1161/circresaha.118.311227 · Cited by 285
Self-citationThe Evolving Future of PCSK9 Inhibitors
Rosenson, R. S., Hegele, R. A., Fazio, S., & Cannon, C. P. (2018) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2018.04.054 · Cited by 264
Self-citationTargeting proprotein convertase subtilisin/kexin type 9 (PCSK9): From bench to bedside
Bao, X., Liang, Y., Chang, H., Cai, T., Feng, B., Gordon, K., Zhu, Y., Shi, H., He, Y., & Xie, L. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01690-3 · Cited by 187
Inclisiran: a small interfering RNA strategy targeting PCSK9 to treat hypercholesterolemia
Banerjee, Y., Pantea Stoian, A., Cicero, A. F. G., Fogacci, F., Nikolic, D., Sachinidis, A., Rizvi, A. A., Janez, A., & Rizzo, M. (2022) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2022.1988568 · Cited by 54
Keep recycling going: new approaches to reduce LDL-C
Klein-Szanto, A. J. P., & Bassi, D. E. (2019) · Biochemical Pharmacology · doi:10.1016/j.bcp.2019.04.003 · Cited by 46
Metadata
- Authors
- Shapiro, M. D., Miles, J., Tavori, H., & Fazio, S.
- Venue
- Annals of Internal Medicine
- Publisher
- American College of Physicians
- Published
- 2018-03-06
- Volume
- 168
- Issue
- 5
- Pages
- 376-379
- ISSN
- 0003-4819 (ISSN-L)
- 1539-3704
- OpenAlex
- W2769104719
- Cited by
- 50
- References
- 2
- FWCI
- 3.79
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.